Schrodinger, Inc. has developed a physics-based software platform, which enables discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions and government laboratories around the world. The Company also leverages its software platform to advance collaborative programs and its own pipeline of therapeutics to address unmet medical needs. The Company operates through two segments: software and drug discovery. The software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on building a portfolio of preclinical and clinical programs, internally and through collaborations, which has advanced to various stages of discovery and development. The Company’s pipeline of drug discovery programs include MALT1, CDC7, Wee1, and SOS1/KRAS.
During the most recent quarter, 5K shares were sold in insider trading.
Insider trading information report provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.